Providers

The LPI/GPR55 axis is a key driver of MAFLD/MASH progression by promoting liver fat accumulation, inflammation, and fibrosis.

Nerandomilast may represent a meaningful addition to the treatment arsenal, offering patients and clinicians a new option for pulmonary fibrosis.

Bireociclib plus fulvestrant significantly improved progression-free survival and response rates in advanced HR-positive breast cancer, with manageable safety and consistent benefits across high-risk subgroups.

The authors assess use of the novel assistant physician (AP) pathway and examine Missouri regulatory changes. They find limited supply impacts of APs and discuss implications.

Even with significant organizational investment in cross-system coordination, primary care providers report a range of challenges in coordinating care with specialists in other health systems.

The standards under this rule will save providers time on paperwork, letting them focus more on patients, says CMS Administrator Mehmet Oz, MD, MBA.

This study assessed the impact of hyperpolypharmacy on hospital readmission risk in 2 Medicare populations and identified effects of postdischarge ambulatory care.

Women aged 35-60 years face higher cancer mortality than men in every generation since the 1930s due to breast and reproductive cancers.

Rural US patients with breast cancer face higher advanced-stage diagnoses, with Black, Hispanic, uninsured patients and those in Southern regions at greatest risk.

Rapid genetic test for IVF identifies FSHR variant in 60 minutes, guiding IVF hormone selection and improving in vitro fertilization success.

Fred D. Lublin, MD, discusses therapy sequencing, deescalation, health equity, and the future of multiple sclerosis (MS) care delivery.

A new meta-analysis links menopausal hormone therapy to higher breast cancer risk with estrogen-progestin therapy, while estrogen-only therapy may lower risk.

Icotrokinra is the first and only interleukin-23–targeted oral peptide approved for plaque psoriasis.

Reproductive health conditions raise child desire but lower pregnancy intentions, spotlighting infertility gaps in women’s health and urging proactive counseling and coverage reform.

GPT-4o reliably scored alopecia areata severity from scalp images, showing strong concordance with experienced dermatology providers without prior AI training.

This commentary examines pressures driving cardiology consolidation, the risks of private equity, and strategies to sustain independent practice while ensuring patient-centered, cost-effective cardiovascular care.

The results are the latest from the multiarm EPCORE-NHL-2 trial, which has studied the bispecific antibody epcoritamab in multiple uses and combinations.

Fred D. Lublin, MD, discusses evolving concepts in MS, including earlier high-efficacy therapy, unrecognized progression, and emerging outcome measures.

Risk-bearing provider organizations rely on physicians to achieve cost savings. The literature on physician-mediated interventions to reduce costs is scant and provides little guidance on effective strategies.

This study of 26,805 cardiologists shows that industry payments (averaging $3958) are linked to increased Medicare costs, with each $10,000 in payment associated with $14.1 higher beneficiary spending.

While clinicians prioritize rapid regrowth, patients with alopecia areata prioritize safety and shared decision-making.

Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen receptor pathway inhibitor.

Genmab’s epcoritamab (Epkinly) streamlines bispecific antibody workflows for DLBCL and follicular lymphoma, cutting chair time, waste, and costs.

Artificial intelligence is emerging as a powerful tool for improving the diagnosis, phenotyping, and treatment of inflammatory skin diseases such as alopecia.

Machine learning–based risk prediction models, particularly gradient boosting, can accurately identify early clinical indicators of CKD.